Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome

被引:79
|
作者
Chen, T-C [1 ]
Hou, H-A [1 ,2 ]
Chou, W-C [1 ,3 ]
Tang, J-L [1 ]
Kuo, Y-Y [4 ]
Chen, C-Y [1 ]
Tseng, M-H [1 ]
Huang, C-F [1 ]
Lai, Y-J [1 ]
Chiang, Y-C [1 ]
Lee, F-Y [5 ]
Liu, M-C [5 ]
Liu, C-W [3 ]
Liu, C-Y [6 ]
Yao, M. [1 ]
Huang, S-Y [1 ]
Ko, B-S [1 ]
Hsu, S-C [3 ]
Wu, S-J [1 ]
Tsay, W. [1 ]
Chen, Y-C [1 ,3 ]
Tien, H-F [1 ]
机构
[1] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Div Hematol,Dept Internal Med, Taipei 10764, Taiwan
[2] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
[3] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10764, Taiwan
[6] Natl Taipei Univ Nursing & Hlth Sci, Dept Nursing, Biostat Consulting Lab, Taipei, Taiwan
来源
BLOOD CANCER JOURNAL | 2014年 / 4卷
关键词
ASXL1; mutation; myelodysplastic syndrome; sequential analyses; prognosis; ACUTE MYELOID-LEUKEMIA; SCORING SYSTEM; STABILITY; TRANSFORMATION; PROGNOSIS; EVOLUTION; RUNX1; JAK2; EZH2;
D O I
10.1038/bcj.2013.74
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recently, mutations of the additional sex comb-like 1 (ASXL1) gene were identified in patients with myelodysplastic syndrome (MDS), but the interaction of this mutation with other genetic alterations and its dynamic changes during disease progression remain to be determined. In this study, ASXL1 mutations were identified in 106 (22.7%) of the 466 patients with primary MDS based on the French-American-British (FAB) classification and 62 (17.1%) of the 362 patients based on the World Health Organization (WHO) classification. ASXL1 mutation was closely associated with trisomy 8 and mutations of RUNX1, EZH2, IDH, NRAS, JAK2, SETBP1 and SRSF2, but was negatively associated with SF3B1 mutation. Most ASXL1-mutated patients (85%) had concurrent other gene mutations at diagnosis. ASXL1 mutation was an independent poor prognostic factor for survival. Sequential studies showed that the original ASXL1 mutation remained unchanged at disease progression in all 32 ASXL1-mutated patients but were frequently accompanied with acquisition of mutations of other genes, including RUNX1, NRAS, KRAS, SF3B1, SETBP1 and chromosomal evolution. On the other side, among the 80 ASXL1-wild patients, only one acquired ASXL1 mutation at leukemia transformation. In conclusion, ASXL1 mutations in association with other genetic alterations may have a role in the development of MDS but contribute little to disease progression.
引用
收藏
页码:e177 / e177
页数:8
相关论文
共 50 条
  • [21] Prognostic Impact of ASXL1 Mutations and Extent of Bone Marrow Dysplasia in Patients with Who -defined Myelodysplastic Syndrome with Ring Sideroblasts
    Mangaonkar, Abhishek
    Lasho, Terra L.
    Finke, Christy
    Gangat, Naseema
    Al-Kali, Aref
    Elliott, Michelle A.
    Begna, Kebede H.
    Alkhateeb, Hassan
    Hanson, Curtis A.
    Ketterling, Rhett P.
    Wolanskyj, Alexandra
    Hogan, William J.
    Pardanani, Animesh
    Litzow, Mark R.
    Tefferi, Ayalew
    Patnaik, Mrinal M.
    BLOOD, 2017, 130
  • [22] Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
    Wu, Shang-Ju
    Tang, Jih-Luh
    Lin, Chien-Ting
    Kuo, Yuan-Yeh
    Li, Li-Yu
    Tseng, Mei-Hsuan
    Huang, Chi-Fei
    Lai, Yen-Jun
    Lee, Fen-Yu
    Liu, Ming-Chih
    Liu, Chia-Wen
    Hou, Hsin-An
    Chen, Chien-Yuan
    Chou, Wen-Chien
    Yao, Ming
    Huang, Shang-Yi
    Ko, Bor-Sheng
    Tsay, Woei
    Tien, Hwei-Fang
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (11) : E277 - E282
  • [23] RUNX1 Mutation Accompanied with Dysregulated Cellular Senescence in Lower-Risk Myelodysplastic Syndrome Patients Is Associated with Disease Progression
    Hruba, Monika
    Vesela, Jitka
    Votavova, Hana
    Merkerova, Michaela Dostalova
    Kundrat, David
    Szikszai, Katarina
    Lauermanova, Marie
    Zemanova, Zuzana
    Jonasova, Anna
    Cermak, Jaroslav
    Belickova, Monika
    BLOOD, 2019, 134
  • [24] NEUROFIBROMATOSIS-1 GENE (NF1) MUTATION IS A RARE GENETIC EVENT IN MYELODYSPLASTIC SYNDROME REGARDLESS OF THE DISEASE PROGRESSION
    KANEKO, H
    HORIIKE, S
    NAKAI, H
    UEDA, Y
    NAKAO, M
    HIRAKAWA, K
    YOKOTA, S
    TANIWAKI, M
    MISAWA, S
    KASHIMA, K
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 1995, 61 (03) : 113 - 116
  • [25] Acute pro-B-Cell lymphoblastic leukemia transformed from myelodysplastic syndrome with an ASXL1 missense mutation: A case report with literature review
    Guo, Zhi-Ping
    Tan, Yan-Hong
    Li, Jian-Lan
    Xu, Zhi-Fang
    Chen, Xiu-Hua
    Xu, Lian-Rong
    ONCOLOGY LETTERS, 2018, 15 (06) : 9745 - 9750
  • [26] Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome
    Ming-En Lin
    Hsin-An Hou
    Cheng-Hong Tsai
    Shang-Ju Wu
    Yuan-Yeh Kuo
    Mei-Hsuan Tseng
    Ming-Chih Liu
    Chia-Wen Liu
    Wen-Chien Chou
    Chien-Yuan Chen
    Jih-Luh Tang
    Ming Yao
    Chi-Cheng Li
    Shang-Yi Huang
    Bor-Sheng Ko
    Szu-Chun Hsu
    Chien-Ting Lin
    Hwei-Fang Tien
    Clinical Epigenetics, 2018, 10
  • [27] Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome
    Lin, Ming-En
    Hou, Hsin-An
    Tsai, Cheng-Hong
    Wu, Shang-Ju
    Kuo, Yuan-Yeh
    Tseng, Mei-Hsuan
    Liu, Ming-Chih
    Liu, Chia-Wen
    Chou, Wen-Chien
    Chen, Chien-Yuan
    Tang, Jih-Luh
    Yao, Ming
    Li, Chi-Cheng
    Huang, Shang-Yi
    Ko, Bor-Sheng
    Hsu, Szu-Chun
    Lin, Chien-Ting
    Tien, Hwei-Fang
    CLINICAL EPIGENETICS, 2018, 10
  • [28] Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
    Yan, Xin
    Xu, Zefeng
    Zhang, Peihong
    Sun, Qi
    Jia, Yujiao
    Qin, Tiejun
    Qu, Shiqiang
    Pan, Lijuan
    Li, Zhanqi
    Liu, Jinqin
    Song, Zhen
    Gao, Qingyan
    Jiao, Meng
    Gong, Jingye
    Wang, Huijun
    Li, Bing
    Xiao, Zhijian
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [29] Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression
    Marum, Justine E.
    Purins, Leanne
    Yeung, David T.
    Parker, Wendy Tara
    Price, David J.
    Wang, Paul P. S.
    Stangl, Doris
    Geogievski, Jasmina
    Chereda, Bradley
    Schreiber, Andreas
    Tuke, Simon J.
    Hughes, Timothy P.
    Branford, Susan
    BLOOD, 2015, 126 (23)
  • [30] Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression
    Xin Yan
    Zefeng Xu
    Peihong Zhang
    Qi Sun
    Yujiao Jia
    Tiejun Qin
    Shiqiang Qu
    Lijuan Pan
    Zhanqi Li
    Jinqin Liu
    Zhen Song
    Qingyan Gao
    Meng Jiao
    Jingye Gong
    Huijun Wang
    Bing Li
    Zhijian Xiao
    Blood Cancer Journal, 13